Importance of radiation therapy for breast cancer patients treated with high-dose chemotherapy and stem cell transplant

被引:12
作者
Buchholz, TA
Tucker, SL
Moore, RA
McNeese, MD
Strom, EA
Jhingrin, A
Hortobagyi, GN
Singletary, SE
Champlin, RE
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[4] Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[5] Univ Texas, MD Anderson Canc Ctr, Dept Hematol, Transplant Serv, Houston, TX 77030 USA
[6] Univ Hlth Sci, Kansas City, MO USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2000年 / 46卷 / 02期
关键词
breast cancer; high-dose chemotherapy; transplant; radiation;
D O I
10.1016/S0360-3016(99)00429-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine local-regional failure rates in breast cancer patients treated with surgery and high-dose chemotherapy with stem cell transplant and to relate local-regional failure to the use and timing of radiation treatment. Methods and Materials: We retrospectively reviewed the records of 165 breast cancer patients treated on institutional protocols with surgery and high-dose chemotherapy with stem cell transplant. All patients had either Stage III disease, 10 or more positive axillary lymph nodes, or 4 or more positive axillary lymph nodes following neoadjuvant chemotherapy, Twelve patients had inflammatory breast cancer. Thirteen patients treated with breast preservation and 5 patients who died from toxicity within 30 days of transplant were excluded from the analyses of local-regional recurrences. In the remaining 147 patients, 108 were treated with adjuvant radiation and 39 were not. The disease stage distribution for these two groups was comparable. The median follow-up for surviving patients was 35 months. Results: The 3- and 5-year actuarial disease-free survival (DFS) for the entire group was 60% and 51%, respectively. The 5-gear rates of freedom from isolated local-regional recurrence were 95% in the patients treated with adjuvant radiation and 86% in the patients who did not receive radiation (p = 0,014, log rank comparison). The 5-year rates of any local-regional recurrence as a first event (isolated recurrences plus those with simultaneous local-regional and distant recurrences) were 92% versus 82%, respectively for patients whose treatment did and did not include radiation (p = 0,038), We could not demonstrate a correlation of the timing of radiation with the risk of Local-regional recurrence. Conclusions: These data indicate that high-dose chemotherapy does not negate the importance of radiation in optimizing local-regional control in patients with high-risk breast cancer. Given the results of recent randomized trials studying postmastectomy radiation, which show that improving local-regional control improves overall survival (OS), we believe that all breast cancer patients with high-risk primary breast cancer who are treated with high-dose chemotherapy with stem cell transplant should receive radiation as a component of their treatment. (C) 2000 Elsevier Science Inc.
引用
收藏
页码:337 / 343
页数:7
相关论文
共 21 条
[1]  
ABE O, 1995, NEW ENGL J MED, V333, P1444
[2]   High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America [J].
Antman, KH ;
Rowlings, PA ;
Vaughan, WP ;
Pelz, CJ ;
Fay, JW ;
Fields, KK ;
Freytes, CO ;
Gale, RP ;
Hillner, BE ;
Holland, HK ;
Kennedy, MJ ;
Klein, JP ;
Lazarus, HM ;
McCarthy, PL ;
Saez, R ;
Spitzer, G ;
Stadtmauer, EA ;
Williams, SF ;
Wolff, S ;
Sobocinski, KA ;
Armitage, JO ;
Horowitz, MM .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) :1870-1879
[3]   POST-MASTECTOMY MEGAVOLTAGE RADIOTHERAPY - THE OSLO AND STOCKHOLM TRIALS [J].
AUQUIER, A ;
RUTQVIST, LE ;
HOST, H ;
ROTSTEIN, S ;
ARRIAGADA, R .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) :433-437
[4]   EFFECT OF DELAY IN RADIATION IN THE COMBINED MODALITY TREATMENT OF BREAST-CANCER [J].
BUCHHOLZ, TA ;
AUSTINSEYMOUR, MM ;
MOE, RE ;
ELLIS, GK ;
LIVINGSTON, RB ;
PELTON, JG ;
GRIFFIN, TW .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 26 (01) :23-35
[5]  
Cox DR., 1988, ANAL SURVIVAL DATA
[6]   CAUSE-SPECIFIC MORTALITY IN LONG-TERM SURVIVORS OF BREAST-CANCER WHO PARTICIPATED IN TRIALS OF RADIOTHERAPY [J].
CUZICK, J ;
STEWART, H ;
RUTQVIST, L ;
HOUGHTON, J ;
EDWARDS, R ;
REDMOND, C ;
PETO, R ;
BAUM, M ;
FISHER, B ;
HOST, H ;
LYTHGOE, J ;
RIBEIRO, G ;
SCHEURLEN, H .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (03) :447-453
[7]   Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy [J].
Diab, SG ;
Hilsenbeck, SG ;
de Moor, C ;
Clark, GM ;
Osborne, CK ;
Ravdin, PM ;
Elledge, RM .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) :1655-1660
[8]   ON THE USE OF CAUSE-SPECIFIC FAILURE AND CONDITIONAL FAILURE PROBABILITIES - EXAMPLES FROM CLINICAL ONCOLOGY DATA [J].
GAYNOR, JJ ;
FEUER, EJ ;
TAN, CC ;
WU, DH ;
LITTLE, CR ;
STRAUS, DJ ;
CLARKSON, BD ;
BRENNAN, MF .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1993, 88 (422) :400-409
[9]   POSTOPERATIVE RADIOTHERAPY IN BREAST-CANCER - LONG-TERM RESULTS FROM THE OSLO STUDY [J].
HOST, H ;
BRENNHOVD, IO ;
LOEB, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1986, 12 (05) :727-732
[10]  
JIMENEZ PL, 1991, EORTC BREAST CANC WO, pA293